Dr. Adrian Harel

Adrian Harel, Ph.DChief Scientific AdministratorProneuron Biotechnologies, IncKiryat Weizmann Science ParkPOB 277Nes Ziona 74101, Israel

Tel :+972 8 940 9550

Fax :+972 8 940 9560

e-mail adrian@proneuron.com

http : //www.proneuron.com /

You have a huge concentration of chemicals for one to two hours and then it goes down," says Adrian Harel, the company's manager.

Adrian Harel, Proneuron company manager, said immune privilege apparently evolved as a defense against diseases that might damage the CNS -- but it also prevents injuries from healing.

"In the central nervous system, structure is very important for function," he said.
...
"We're sure we won't initially be able to grow 100 percent of the nerves," said Harel.
...
When we purify we often end up with almost nothing," said Harel, describing the frustrations.

Adrian Harel, PhDDr. Harel brings to the company hands-on management experience in young biotechnology companies.He established and managed Israeli start-ups such as ProNeuron, Heal-Or, and the Jerusalem Biotechnology Center, a regional biotechnology incubator.Dr. Harel received his PhD in Neurobiology from the Weizmann Institute of Science in Rehovot, Israel, as well as a BA degree in Business Administration from the University of Haifa, Israel.

Adrian Harel, Proneuron company manager, said immune privilege apparently evolved as a defense against diseases that might damage the CNS -- but it also prevents injuries from healing.

"In the central nervous system, structure is very important for function," he said."The connection between the nerves is very delicate; once it's disturbed, its function is, too."

Indeed, species with simpler neurological systems, like fish, can recover from CNS injuries.

...
"We're sure we won't initially be able to grow 100 percent of the nerves," said Harel."The outcome will be variable and depend on how much physical therapy is done and other factors."

To date, nerve regeneration has only been conducted on laboratory animals.But Proneuron expects to begin phase one clinical trials on humans before the end of the year, after the U.S. Food and Drug Administration gives the go-ahead.

Proneuron has other, related technologies further up the development pipeline.
...
When we purify we often end up with almost nothing," said Harel, describing the frustrations.

To speed up development in IPF, Proneuron hopes to enlist a major pharmaceuticals company as a partner.

Text

Text Text

"This is the FDA's first trial approval for a therapy aimed at regenerating nerve cells damaged by a complete spinal cord injury, a treatment that addresses a dire medical need," said Dr. Adrian Harel, Manager of Proneuron Biotechnologies (Israel) Ltd, the company's R&D and manufacturing subsidiary.

The clinical trial has been authorized by the Israeli Ministry of Health and will be conducted at two medical centers in Israel.
...
Dr. Adrian HarelProneuron Biotechnologies (Israel) Ltd.POB 277, Ness-ZionaIsrael 74101

Tel: +972-8-940-9550Fax: +972-8-940-9560

Adrian Harel, Proneuron company manager, said immune privilege apparently evolved as a defense against diseases that might damage the CNS -- but it also prevents injuries from healing.

"In the central nervous system, structure is very important for function," he said.
...
"We're sure we won't initially be able to grow 100 percent of the nerves," said Harel.
...
When we purify we often end up with almost nothing," said Harel, describing the frustrations.

"This is the FDA's first trial approval for a therapy aimed at regenerating nerve cells damaged by a complete spinal cord injury, a treatment that addresses a dire medical need," says Adrian Harel, Ph.D., company manager at Proneuron.
...
"We're sure we won't initially be able to grow 100% of the nerves," says Dr. Harel.